

Technology Development Group

Request Information

Anti-PSA lgG

Tech ID: 29782 / UC Case 2014-845-0

SUMMARY

Researchers at UCLA have developed chimeric IgG specific for prostate-specific antigen (PSA) in human and mouse cells.

BACKGROUND

Prostate-specific antigen (PSA) is a substance made by cells in the prostate gland. Physicians use high PSA levels (above 4 nanograms per milliliter) as a blood biomarker for prostate cancer. Given this, a PSA antibody with high specificity to human PSA would benefit clinical diagnosis of prostate cancer.

Available Technologies

INNOVATION

Researchers at UCLA have developed a chimeric IgG specific antibody for the PSA in human and mouse cells. The variable regions of this antibody are those of the murine monoclonal antibody AR47.47. This novel antibody was expressed in murine myeloma cell lines, and is therefore cost efficient and easy to produce. It is properly assembled and secreted and binds PSA antigen

APPLICATIONS

- Detect levels of PSA in prostate cancer patients
- > Detect levels of PSA in experimental procedures performed in research laboratories

ADVANTAGES

Specific to PSA

Developed in murine myeloma cell lines:

- Cost-efficient
- Easy to produce large quantities of antibody

STATE OF DEVELOPMENT

Antibody has been developed and validated.

Contact Our Team

Permalink

CONTACT

UCLA Technology Development Group ncd@tdg.ucla.edu tel: 310.794.0558.



INVENTORS

Penichet, Manuel L.

OTHER INFORMATION

KEYWORDS

Antibody, prostate specific antigen,

PSA, prostate cancer biomarker,

diagnosis, diagnostic

CATEGORIZED AS

Medical

- Diagnostics
- ► Disease: Cancer
- Research Tools
- Research Tools
 - Antibodies

RELATED CASES 2014-845-0

Gateway to Innovation, Research and Entrepreneurship

UCLA Technology Development Group

10889 Wilshire Blvd., Suite 920,Los Angeles,CA 90095 https://tdg.ucla.edu Tel: 310.794.0558 | Fax: 310.794.0638 | ncd@tdg.ucla.edu © 2018, The Regents of the University of California Terms of use Privacy Notice

